Bayer AG (BAYN) Given Consensus Recommendation of “Buy” by Brokerages
Bayer AG (FRA:BAYN) has been assigned a consensus rating of “Buy” from the twenty-two brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is €123.00 ($146.43).
BAYN has been the topic of a number of recent analyst reports. Nord/LB reaffirmed a “neutral” rating on shares of Bayer in a report on Wednesday, December 27th. Barclays set a €105.00 ($125.00) price objective on Bayer and gave the stock a “sell” rating in a report on Monday, November 6th. DZ Bank reaffirmed a “buy” rating on shares of Bayer in a report on Monday, December 11th. Baader Bank set a €120.00 ($142.86) price objective on Bayer and gave the stock a “neutral” rating in a report on Wednesday, September 13th. Finally, Independent Research set a €120.00 ($142.86) price objective on Bayer and gave the stock a “neutral” rating in a report on Tuesday, November 28th.
Bayer (FRA:BAYN) traded down €0.68 ($0.81) during trading on Tuesday, hitting €107.20 ($127.62). The stock had a trading volume of 1,965,729 shares. Bayer has a twelve month low of €99.69 ($118.68) and a twelve month high of €123.82 ($147.40). The stock has a market capitalization of $88,470.00 and a PE ratio of 28.74.
ILLEGAL ACTIVITY NOTICE: “Bayer AG (BAYN) Given Consensus Recommendation of “Buy” by Brokerages” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/bayer-ag-bayn-given-consensus-recommendation-of-buy-by-brokerages/1800476.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.